Ecommerce ordering is currently available for USA customers. International customers should contact their sales representative for orders.


  • Bio-Type Serum/Plasma
  • Method ELISA
  • CE Y
  • # of Tests 96 Wells
  • Range 10 – 1000 pg/mL
  • Sensitivity 10 pg/mL
  • Sample Volume 10 uL
  • Incubation Time(s) 180 / 120 / 20 / 10 min
  • Storage Conditions 2° C - 8° C and -20 ° C
  • SKU:  EIA2396
  • Category: Immunology/Hematology
  • $228.00
Approximate Lead Time 1 - 2 Weeks
For Bulk Orders of 35+ Kits, please Contact Us


The DRG TGF-?2 ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of TGF-?2 in serum, plasma and cell culture supernatant. Transforming growth factor-? (TGF-?) is a multipotent Cytokine with cell- and dose-dependent activities. This molecule is produced by a number of cells and tissue types, e.g. thrombocytes, bone tissue, placenta and kidneys. TGF-?2 is not produced by blood platelets, contrary to TGF-?1. This potent Cytokine modulates embryonic development, bone formation, mammary development, wound healing, hematopoiesis, cell cycle progression and the production of the extracellular matrix. TGF-?2 – null mice were shown to exhibit perinatal mortality and a wide range of developmental defects for a single gene description which include cardiac, lung, craniofacial, limb, spinal column, eye, inner ear and urogenitial defects. TGF-?2 has been shown to be a potent growth inhibit factor in the regulation of postnatal cerebellar neurons and neuroblast proliferation. TGF-?2 has been detected in tear fluid. TGF-?2 levels are elevated in the vitreous of patients with proliferative diabetic retinopathy. Elevated plasma levels of TGF-?2 have been described in patients with disseminated malignant melanoma. TGF-?2 concentrations are furthermore elevated in Parkinson’s disease in ventricular cerebrospinal fluid. The DRG TGF-?2 ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Prior to testing the standards and patient samples are diluted in assay buffer, acidified with HCl and then neutralized with Neutralization Buffer. Afterwards, the neutralized standards and samples are added to the antibody coated (polyclonal) microtiter wells. After the first incubation the unbound sample material is removed by washing. Then a biotinylated mouse anti TGF-?2 antibody and the Streptavidin-HRP Enzyme complex are incubated in succession. An immuno enzyme sandwich complex is formed. After incubation the unbound conjugate is washed off. Having added the substrate solution, the intensity of colour developed is proportional to the concentration of TGF-?2 in the patient sample.